These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21097803)

  • 1. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.
    Dejaco C; Duftner C; Cimmino MA; Dasgupta B; Salvarani C; Crowson CS; Maradit-Kremers H; Hutchings A; Matteson EL; Schirmer M;
    Ann Rheum Dis; 2011 Mar; 70(3):447-53. PubMed ID: 21097803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
    Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
    Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
    Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
    JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.
    Nothnagl T; Leeb BF
    Drugs Aging; 2006; 23(5):391-402. PubMed ID: 16823992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission.
    Leeb BF; Rintelen B; Sautner J; Fassl C; Bird HA
    Arthritis Rheum; 2007 Jun; 57(5):810-5. PubMed ID: 17530664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).
    Leeb BF; Bird HA; Nesher G; Andel I; Hueber W; Logar D; Montecucco CM; Rovensky J; Sautner J; Sonnenblick M
    Ann Rheum Dis; 2003 Dec; 62(12):1189-94. PubMed ID: 14644857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Methods for assessment of disease activity of polymyalgia rheumatica].
    Reisch M; Dejaco C
    Z Rheumatol; 2023 Jun; 82(5):368-379. PubMed ID: 37184675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.
    McCarthy EM; MacMullan PA; Al-Mudhaffer S; Madigan A; Donnelly S; McCarthy CJ; Molloy ES; Kenny D; McCarthy GM
    J Rheumatol; 2014 May; 41(5):931-7. PubMed ID: 24692520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
    Salvarani C; Cantini F; Niccoli L; Macchioni P; Consonni D; Bajocchi G; Vinceti M; Catanoso MG; Pulsatelli L; Meliconi R; Boiardi L
    Arthritis Rheum; 2005 Feb; 53(1):33-8. PubMed ID: 15696567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of the polymyalgia rheumatica activity score in primary care practice.
    Binard A; Lefebvre B; De Bandt M; Berthelot JM; Saraux A;
    Ann Rheum Dis; 2009 Apr; 68(4):541-5. PubMed ID: 18477738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.
    Dasgupta B; Cimmino MA; Maradit-Kremers H; Schmidt WA; Schirmer M; Salvarani C; Bachta A; Dejaco C; Duftner C; Jensen HS; Duhaut P; Poór G; Kaposi NP; Mandl P; Balint PV; Schmidt Z; Iagnocco A; Nannini C; Cantini F; Macchioni P; Pipitone N; Amo MD; Espígol-Frigolé G; Cid MC; Martínez-Taboada VM; Nordborg E; Direskeneli H; Aydin SZ; Ahmed K; Hazleman B; Silverman B; Pease C; Wakefield RJ; Luqmani R; Abril A; Michet CJ; Marcus R; Gonter NJ; Maz M; Carter RE; Crowson CS; Matteson EL
    Ann Rheum Dis; 2012 Apr; 71(4):484-92. PubMed ID: 22388996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.
    Mackie SL; Arat S; da Silva J; Duarte C; Halliday S; Hughes R; Morris M; Pease CT; Sherman JW; Simon LS; Walsh M; Westhovens R; Zakout S; Kirwan JR
    J Rheumatol; 2014 Apr; 41(4):819-23. PubMed ID: 24488422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR).
    Lee JH; Choi ST; Kim JS; Yoon BY; Kwok SK; Kim HS; Kim YS; Song JS; Lee SH; Kim HR
    Rheumatol Int; 2013 Jun; 33(6):1475-80. PubMed ID: 23184033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes Measured in Polymyalgia Rheumatica and Measurement Properties of Instruments Considered for the OMERACT Core Outcome Set: A Systematic Review.
    Twohig H; Owen C; Muller S; Mallen CD; Mitchell C; Hider S; Hill C; Shea B; Mackie SL
    J Rheumatol; 2021 Jun; 48(6):883-893. PubMed ID: 32739892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.
    Helliwell T; Brouwer E; Pease CT; Hughes R; Hill CL; Neill LM; Halls S; Simon LS; Mallen CD; Boers M; Kirwan JR; Mackie SL
    J Rheumatol; 2016 Jan; 43(1):182-6. PubMed ID: 26568595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity.
    Cimmino MA; Parodi M; Montecucco C; Caporali R
    BMC Musculoskelet Disord; 2011 May; 12(1):94. PubMed ID: 21569559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica.
    Dejaco C; Singh YP; Perel P; Hutchings A; Camellino D; Mackie S; Matteson EL; Dasgupta B
    Ann Rheum Dis; 2015 Oct; 74(10):1808-17. PubMed ID: 26359489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A disease activity score for polymyalgia rheumatica.
    Leeb BF; Bird HA
    Ann Rheum Dis; 2004 Oct; 63(10):1279-83. PubMed ID: 15361387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios.
    Binard A; De Bandt M; Berthelot JM; Saraux A;
    Arthritis Rheum; 2007 Apr; 57(3):481-6. PubMed ID: 17394219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitions of and Instruments for Disease Activity, Remission, and Relapse in Polymyalgia Rheumatica: A Systematic Literature Review.
    Bolhuis TE; Bosch P; Falzon L; Owen CE; Yates M; Mackie SL; van der Maas A; Dejaco C
    Rheumatology (Oxford); 2024 Aug; ():. PubMed ID: 39133187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.